Abstract：
OBJECTIVE: Ulcerative colitis (UC) clinical guidelines include the best available evidence, although not all clinical situations are answered, so their management can be controversial. The aim of this study is to identify the situations of mild to moderate UC susceptible to controversy and to evaluate the degree of agreement or disagreement with specific proposals.
METHODS: Inflammatory bowel disease (IBD) expert discussion meetings were used to identify criteria, attitudes and opinions regarding the management of UC. A Delphi questionnaire was then developed with 60 items regarding antibiotics, salicylates and probiotics; local, systemic and topical corticosteroids; and immunosuppressants.
RESULTS: Consensus was reached in 44 statements (73.3%); 32 in agreement (53.3%) and 12 in disagreement (20.0%). Some of them were: it is not necessary the systematic use of antibiotics despite the severity of the outbreak, being reserved when there is suspicion of infection or systemic toxicity; when faced with a mild-moderate outbreak of UC and in patients who do not respond to aminosalicylates, it is appropriate to use a dose of beclomethasone of 10mg/day for one month and 5mg/day for another month; it is advised that the dose of azathioprine be administered in a single dose.
CONCLUSIONS: IBD experts agree on most of the proposals identified for managing mild to moderate UC and there is a need for scientific evidence in some specific situations where expert opinion may be helpful.
METHODS: Inflammatory bowel disease (IBD) expert discussion meetings were used to identify criteria, attitudes and opinions regarding the management of UC. A Delphi questionnaire was then developed with 60 items regarding antibiotics, salicylates and probiotics; local, systemic and topical corticosteroids; and immunosuppressants.
RESULTS: Consensus was reached in 44 statements (73.3%); 32 in agreement (53.3%) and 12 in disagreement (20.0%). Some of them were: it is not necessary the systematic use of antibiotics despite the severity of the outbreak, being reserved when there is suspicion of infection or systemic toxicity; when faced with a mild-moderate outbreak of UC and in patients who do not respond to aminosalicylates, it is appropriate to use a dose of beclomethasone of 10mg/day for one month and 5mg/day for another month; it is advised that the dose of azathioprine be administered in a single dose.
CONCLUSIONS: IBD experts agree on most of the proposals identified for managing mild to moderate UC and there is a need for scientific evidence in some specific situations where expert opinion may be helpful.
摘要：
目的：溃疡性结肠炎（UC）临床指南包括现有的最佳证据，虽然不是所有的临床情况都能得到回答，所以他们的管理可能会引起争议。这项研究的目的是确定轻度至中度UC容易引起争议的情况，并评估与具体建议的一致或分歧程度。
方法：使用炎症性肠病（IBD）专家讨论会确定标准，对UC管理的态度和意见。然后开发了一份德尔菲问卷，包含60个关于抗生素的项目，水杨酸盐和益生菌；局部，全身和局部皮质类固醇和免疫抑制剂。
结果：在44个陈述中达成共识（73.3％）；32个意见一致（53.3％），12个意见不一致（20.0％）。其中一些是：尽管疫情严重，但没有必要系统地使用抗生素，当怀疑感染或全身毒性时，保留；当面临轻度-中度UC爆发以及对氨基水杨酸盐无反应的患者时，适当使用剂量为10mg/天的倍氯米松一个月，5mg/天的剂量为另一个月；建议以单剂量施用硫唑嘌呤。
结论：IBD专家同意大多数已确定的治疗轻度至中度UC的建议，并且在某些特定情况下需要科学证据，专家意见可能会有所帮助。
方法：使用炎症性肠病（IBD）专家讨论会确定标准，
结果：在44个陈述中达成共识（73.3％）；32个意见一致（53.3％），12个意见不一致（20.0％）。
结论：IBD专家同意大多数已确定的治疗轻度至中度UC的建议，并且在某些特定情况下需要科学证据，专家意见可能会有所帮助。
